Geeta Swamy, MD, & Chip Walter, MD, MPH, Leading Studies on 2 COVID-19 Vaccine Clinical Trials, NIH-NIAID/CDC-funded Safety Assessment Project

Duke University's Geeta Swamy, MD, and Emmanuel (Chip) Walter, MD, MPH, are Co-Principal Investigators for the NIH-NIAID Vaccine Treatment and Evaluation (VTEU) and CDC-funded Clinical Immunization Safety Assessment Project and for a current COVID-19 vaccine trial (Pfizer/BioNTech). Additionally, Dr. Swamy is Co-Investigator and Dr. Walter is Principal Investigator on a planned clinical trial for a SARS-COV-2 (COVID-19) vaccine through the COVID-19 Prevention Network (COVPN).

Duke recruitment for the Pfizer/BioNTech SE trial has completed, and recruitment for the COVID-19 Prevention Network Phase 3 randomized, placebo-controlled trial among healthy adults, ages 18- 85 years, is planned. The trial is seeking 30,000+ participants.

Dr. Swamy, Associate Professor of Ob/Gyn, is a maternal-fetal medicine specialist and serves as Duke Ob/Gyn's Vice Chair for Research and Faculty Development, as well as Duke University Associate Vice President for Research and Duke University School of Medicine Vice Dean for Scientific Integrity. Her responsibilities include leading the Duke Office of Scientific Integrity (DOSI), which includes the Advancing Scientific Integrity, Services and Training (ASIST) initiative, conflict of interest disclosure and management, clinical research quality management, misconduct in research), and institutional research incident response. She also oversees the Duke Office of Research Initiatives (DORI).

Dr. Walter is a pediatric infectious diseases specialist, pediatrician, primary care doctor and Professor of Pediatrics. He serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. He currently is the Principal Investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). Dr. Walter's focused area of interest includes vaccine development, vaccine safety, vaccine coverage, prevention and treatment of infectious diseases.

Share